medigraphic.com

2002, Number 1-2

<< Back Next >>

Rev Hosp M Gea Glz 2002; 5 (1-2)

Diabetic nephropathy

Torres VA, Zacarías CR

Language: Spanish
References: 73
Page: 24-32
PDF size: 108.45 Kb.


ABSTRACT

Diabetic nephropathy is one of the most important complications of diabetes mellitus with definite repercussions in the quality of life and the global prognosis of the disease. It is now known that certain conditions like hyperglucemic lack of control and arterial hypertension elicit the structural damage of nephrons initially targeted at the mesangium and later manifested as a diffuse insult, evolving phases that correlate well with Mogensen’s clinical stages that end up in end stage renal failure. The first early indicator of diabetic nephropathy is microalbuminuria; during this stage therapeutic interventions should be undertaken: diet modifications, strict glycemic and blood pressure control and the use of angiotensin converting enzyme inhibitor or angiotensin receptor blockers which have proven preventing effects on renal damage in diabetic patients. Other factors like smoking, hyperlipidemia, hyperhomocystinemia and urinary infections should be considered and treated as part of the integral therapeutic management of diabetic nephropathy.


REFERENCES

  1. Breyer JA. Diabetic nephropathy in insulin-dependent patients. Am J Kidney Dis 1992; 20: 533-547.

  2. Nelson RG, Knowler WC, Pettitt DJ et al. Assessing risk of overt nephropathy in diabetic patients from albumin excretion in untimed urine specimens. Arch Intern Med 1991; 151: 1761-1765.

  3. Poulsen JE. Features to history of diabetology Copenhagen. Muskgaard 1982; 11-17.

  4. Hayashi H, Karasawa R, Inn H et al. An electron microscopic study of glomeruli in Japanese patients with non-insulin dependent diabetes mellitus. Kidney Int 1992; 41: 749-757.

  5. UK prospective diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38 UK prospective diabetes Study Group. BMJ 1998; 13: 933-8.

  6. The Diabetes Control and Complications Trial Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial. Kidney Int 1995; 47: 1703-1720.

  7. Microalbuminuria Collaborative Study Group UK: Intensive therapy and progressive to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. BMJ 1995; 311: 973-977.

  8. Knowler WC, Kunzelman CL. Population comparisons of the frequency of diabetic nephropathy. In: Mongensen CE. ed. The Kidney and hypertension in diabetes mellitus. Boston: Mnijhoff 1988; 25-32.

  9. Nelson RG, Pettitt DJ, Carraher MJ et al. Effect of proteinuria on mortality in NIDDM. Diabetes 1988; 37: 1499-1504.

  10. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. Arch Intern Med 1997; 157: 1413-1418.

  11. Nelson RG, Newman JM, Knowler WC et al. Incidence of end-stage renal disease in type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia 1988: 31: 730-736.

  12. Ballard DJ, Humphrey LL, Melton LJ III et al. Epidemiology of persistent proteinuria in type II diabetes mellitus: Population-based study in Rochester, Minnesota. Diabetes 1998; 37: 405-412.

  13. Striker GE, Agodoa LL, Held P et al. Kidney disease of diabetes mellitus (diabetic nephropathy): Perspectives in the United States. J Diabetes Complications 1992; 5: 51-52.

  14. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984; 311: 89-93.

  15. Viberti GC, Bilous RW, Mackintosh D et al. Long term correction of hyperglycaemia and progression of renal failure in insulin dependent diabetes. BMJ 1983; 286: 598-602.

  16. Gall M-A, Borch-Johnsen K, Hougaard P et al. Albuminuria and poor glycemic control predicts mortality in NIDDM. Diabetes 1995; 44: 1303-1309.

  17. Fiorettto P, Stffes MW, Sutherland DER, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339: 69-75.

  18. Mauer SM, Steffes Hw, Connet J et al. The development of lesions in the glomerular basement membrane and mesangium after transplantation of normal kidneys to diabetic patients. Diabetes 1983; 32: 948-952.

  19. Abouna GH, Kremer GD, Daddh SK et al. Reversal of diabetic nephropathy in human cadaveric kidneys after transplantation into non diabetic recipients. Lancet 1983; 2: 1274-1276.

  20. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304-309.

  21. Tamborlane WV, Puklin JE, Bergman M et al. Long-term improvement of metabolic control with the insulin pump does not reverse diabetic microangiopathy. Diabetes Care 1982; 5(suppl 1): 58-64.

  22. Kalbag JB, Walter YH, Nedelman JR et al. Mealtime glucose regulation with nateglinide in healthy volunteers. Diabetes care 2001; 24: 73-77.

  23. Gall M-A, Hougaard P, Borch-Johnsen K et al. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: Prospective, observational study. BMJ 1997; 314: 783-788.

  24. Viberti GC, Keen H, Wiseman MJ. Raise arterial pressure in patients of proteinuric insulin-dependent diabetics. Br Med J 1987; 295: 515-517.

  25. Fagerudd JA, Tarnow L, Jacobsen P et al. Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes 1998; 47: 439-444.

  26. Hostetter TH. Pathogenesis of diabetic glomerulopathy: Hemodynamic considerations. Semin Nephrol 1990; 10: 219-227.

  27. Krolewski AS et al. Predisposition to hypertension and susceptibility to renal diseases insulin-dependent diabetics mellitus. N Engl J Med 1988; 318: 140-145.

  28. Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria, and the progression of renal disease: The modification of diet in renal disease study. Ann Intern Med 1995; 123: 754-762.

  29. The effect of Goldbaltt hypertension on development of the glomerular lesions of diabetes mellitus in the rat. Diabetes 1978; 27: 738-744.

  30. Hosstetter TH, Troy JL, Brenner BH. Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 1981; 19: 410-415.

  31. Osterby R, Gall M-A, Schmitz A et al. Glomerular structure and function in proteinuric type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 1064-1070.

  32. Tesfamariam B, Brown ML. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest 1991; 87: 1643-1648.

  33. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-1321.

  34. Rudberg S, Osterby R, Dalquist G. Predictors of renal morphological changes in the early stage of microalbuminuria in adolescents with IDDM. Diabetes Care 1997; 20: 265-271.

  35. Parving H-H, Gall M-A, Skott P et al. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 1992; 41: 758-762

  36. Vernier RL, Steffes MW, Sisson-Ross S et al. Heparan sulfate proteoglycan in the glomerular basement membrane in type 1 diabetes mellitus. Kidney Int 1992; 41: 1070-1080.

  37. Osterby R, Gall M-A, Schmitz A et al. Glomerular structure and function in proteinuric type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 1064-1070.

  38. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 1984; 310: 356-360.

  39. Pagtalunan ME, Miller PL, Jumping-Eagle S. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1996; 99: 342-348.

  40. Steffes MW, Bilous RW, Sutherland DER et al. Cell and matrix components of the glomerular mesangium in type 1 diabetes. Diabetes 1992; 41: 679-684.

  41. Berkman J, Riflin H. Unilateral nodular diabetic glomeruloesclerosis (Kimmmelstiel-Wilson): report of case Metabolism 1973; 22: 715.

  42. Mongensen CE, Schmitz O. The diabetic kidney from hyperfiltration and microalbuminuria to end-stage renal failure. Med Clin North Am 1998; 1: 465-492.

  43. Mathiesen ER, Ronn B, Jensen T et al. Relationship between blood pressure and urinary albumin excretion in development of microalbuminuria. Diabetes 1990; 39: 245-249.

  44. Mathiesen ER, Oxenboll B, Johansen K et al. Incipient nephropathy in type 1 (insulin-dependent) diabetes. Diabetologia 1984; 26: 406-410.

  45. Viberti GC, Hill RD, Jarrett RJ et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982; i: 1430-1432.

  46. Mogensen CE, Chachati A, Christensen CK et al. Microalbuminuria: An early marker of renal involvement in diabetes. Uremia Invest 1985; 9: 85-9.

  47. Chiristiansen JS, Fradsen N, Srendensen PA et al. Rapid changes in Kidney function in diabetic and normal man. Acta Endocrinol 1981; 242: 11-221.

  48. Torffvit O, Agardh C-D, Mathiasson A. A lack of association between cystopathy and progression of diabetic nephropathy in insulin-dependent diabetes mellitus. Scand J Urol Nephrol 1997; 31: 365-369.

  49. Vejlsgaard R. Urinary tract infection and diabetes: Diagnosis and treatment. In: Mogensen CE (ed): The Kidney and Hypertension in Diabetes Mellitus. Kluwer Academic Publishers, Boston, 1996: 433-437.

  50. Eknoyan G. Renal papillary necrosis in diabetic patients. In: Mogensen CE (ed): The Kidney and Hypertension in Diabetes Mellitus. Kluwer Academic Publishers, Boston, 1996: 461-468.

  51. De Cosmo S, Bacci S, Pairs GP et al. High prevalence of risk factors for cardiovascular disease in parents of IDDM patients with albuminuria. Diabetologia 1997; 40: 1191-1196.

  52. Ravid M, Neumann L, Lishner M. Plasma lipids and the progression of nephropathy in diabetes mellitus type II: Effect of ACE inhibitors. Kidney Int 1995; 47: 907-910.

  53. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation products on collagen covalently trap low-density lipoproteins. Diabetes 1985; 34: 938-941.

  54. Sato A, Tarnow L, Hans P. Increased left ventricular mass in normotensive type 1 diabetic patients with diabetic nephropathy. Diabetes Care 1998; 21: 1534-1539.

  55. Nielsen FS, Ali S, Rossing P et al. Left ventricular hypertrophy in non-insulin dependent diabetic patients with and without diabetic nephropathy. Diabet Med 1997; 14: 538-546.

  56. Borch-Johnsen K, Kreiner S. Proteinuria: Value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. BMJ 1987; 294: 1651-1654.

  57. Kalbac JB, Walter YH, Nedelman JR. Mealtime glucose regulation with nateglinide in healthy volunteers. Diabetes Care 2001; 24: 73-77.

  58. Kasiske BL, Kalil R, Ma JZ et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 1993; 118: 129-138.

  59. Ravid M, Savin H, Jutrin I et al. Long-term stabilizing effect of angiotensin converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577-581.

  60. Parving HH, Anderson AR, Smith et al. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J 1987; 294: 1443-7.

  61. Ravid M, Lang R, Rachmani R et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. Arch Intern Med 1996; 156: 286-289.

  62. Bakris GL, Willians M, Dworkin L et al. National kidney foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36: 646-661.

  63. H, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, the RENAAL Study Investigators Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.

  64. Parving H-H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the Development of Diabetic Nephropathy in patients whit Type 2 Diabetes. N Engl J Med 2001; 345: 870-878.

  65. Lewis EJ, Hunsicker LG, Clarke WR, Berl T et al. The Collaborative Study Group Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.

  66. Blackshear JI, Schwartz GL. Step care therapy for hypertension in diabetic patients. Mayo Clin Proc 2001; 76: 1266-1274.

  67. Ritz EI, Rychlik M. Blood pressure in diabetic nephropathy-current controversies. J Intern Med 2001; 249: 215-223.

  68. The Microalbuminuria Captopril Study Group: Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996; 39: 587-593.

  69. Rossing P, Hommel E, Smidt UM et al. Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 1993; 42: 715-719.

  70. Parving HH, Hommel E, Damkjaer NM, Glese J. Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy. BMJ 1989; 299: 533-6.

  71. Sano T, Kawamura T, Matsumae H et al. Effects of long-term enalapril treatment on persistent microalbuminuria in weil-controlled hypertensive and normotensive NIDDM patients. Diabetes Care 1994; 7: 420-424.

  72. Ritz E, Orth SR. Prymary care: nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341: 1127-1133.

  73. Markell MS, Friedman EA. Diabetic nephropathy-Management of the end stage patient. Diabetes Care 1992; 15: 1226-1238.




2020     |     www.medigraphic.com